2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6056 Minimal pre-transplant cytoreduction is not associated with inferior outcomes after allogeneic transplantation for myelodysplastic syndromes: A Mayo Clinic IPSS-M–Stratified analysis

Angel Luis OROSCO-TTAMINA, MD, MBA, Talha Tahir, MD2, Hemant Murthy, MD3, Hassan B Alkhateeb, M.D.4, Aref Al-Kali, M.D.5, Lisa Sproat, M.D.6, Nathan Punwani, M.D.7, Saurabh Chhabra, MD, MBBS8, Jeanne Palmer, MD9, Talha Badar, MD10, James Foran, FRCPC11, Mohamed Kharfan-Dabaja, MD12, Nandita Khera, MD13, Cecilia Arana Yi, M.D.14
1 Mayo Clinic, Phoenix, Arizona, United States
2 Mayo Clinic, Phoenix, Arizona, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Phoenix, Arizona, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Mayo Clinic, Phoenix, Arizona, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Jacksonville, Florida, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Jacksonville, Florida, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Mayo Clinic, Phoenix, Arizona, United States

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative therapy for myelodysplastic syndromes (MDS), but the value of cytoreduction before transplant remains unresolved. Although pre-transplant cytoreduction is commonly pursued to reduce marrow blasts before allo-HCT, the optimal strategy and target blast threshold remain uncertain. Some patients treated with a bridging strategy never reach transplant because of progression or toxicity. Although IPSS-M predicts post-transplant survival more accurately than IPSS-R, few real-world series have assessed pre-transplant treatment intensity within a molecular risk framework.

 

Methods: We retrospectively studied consecutive adults with de novo MDS undergoing first allo-HCT at three Mayo Clinic sites (Rochester 2017-2025, Arizona 2017-2024, Florida 2019-2025). Patients lacking diagnostic next-generation sequencing (obtained at diagnosis). Patients were classified a priori according to pre-transplant MDS-directed therapy as having received minimal or no cytoreduction (0 to 1 cycle) versus cytoreduction (2 or more cycles), using a prespecified rule that restricted countable therapy to HMA-based and intensive regimens. IPSS-M was recalculated at diagnosis using hemoglobin, platelets, marrow blasts, IPSS-R cytogenetic category, and 31-gene molecular data. Endpoints from transplant were overall survival (OS), relapse-free survival (RFS), and cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) as competing risks. Cox models adjusted for IPSS-M category, age, conditioning intensity, donor type, HCT-CI, and disease status at HCT.

 

Results: 169 patients were included (Rochester 71, Arizona 48, Florida 50). Median age at diagnosis was 63 years (range 20-75); 62% were male. IPSS-M was Very Low 2%, Low 12%, Moderate-Low 22%, Moderate-High 16%, High 23%, Very High 25%. Conditioning was reduced-intensity in 70% and myeloablative or high-dose in 29%; donors were matched unrelated 70%, matched related 17%, haploidentical 12%. Median diagnostic marrow blasts were 7%.

 

Twenty-four patients (14%) received 0-1 cycle and 145 (86%) received >=2 cycles (median 4, range 2-18). Among cytoreduced patients, HMA monotherapy predominated (65%), followed by HMA plus venetoclax (28%) and intensive or targeted therapy (7%). Age, IPSS-M, cytogenetic risk, donor type, and blast category at transplant were comparable between groups; the minimal-cytoreduction group had a shorter interval from diagnosis to HCT (median 4.0 vs 9.4 months).

 

At a median follow-up of 40 months among survivors, 3-year OS was 60% (95% CI 39-76) with minimal cytoreduction versus 58% (95% CI 49-66) with >=2 cycles (P=0.76). Three-year RFS was 55% versus 52% (P=0.72), CIR 21% versus 19% (P=0.66), and NRM 25% versus 29% (P=0.54). Cytoreduction treatment intensity was not independently associated with OS (HR 0.93; 95% CI 0.48-1.80; P=0.83) or RFS (HR 0.97; 95% CI 0.51-1.83; P=0.92). IPSS-M remained independently prognostic for OS (HR 1.31 per category; 95% CI 1.12-1.54; P<0.01) and relapse (HR 1.44; 95% CI 1.16-1.79; P<0.01). Among patients with diagnostic blasts >=10%, 3-year OS was 57% versus 54% (P=0.84). NRM, mainly infection and steroid-refractory graft-versus-host disease, accounted for approximately 70% of deaths in both groups.

 

Conclusions: In this multi-site real-world cohort, proceeding to allo-HCT with no or minimal cytoreduction was not associated with inferior survival or greater relapse risk after adjustment for molecular risk, including among patients with >=10% diagnostic blasts. IPSS-M remained independently prognostic regardless of pre-transplant treatment exposure. These findings suggest that transplantation should not necessarily be delayed solely to administer additional cytoreductive therapy when a suitable donor and transplant plan are available. Interpretation is limited by the retrospective design, small minimal-cytoreduction group, non-random treatment allocation, and selection of patients who successfully reached transplantation; prospective validation is warranted.
Angel Luis OROSCO-TTAMINA, MD, MBA: Onviv, Inc. - Honoraria